CALT - Calliditas partner wins China nod for kidney disease therapy
2023-11-24 08:00:38 ET
More on Calliditas Therapeutics
- Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point
- Calliditas stock dips as losses widen in Q3
- Seeking Alpha’s Quant Rating on Calliditas Therapeutics
- Historical earnings data for Calliditas Therapeutics
- Financial information for Calliditas Therapeutics
For further details see:
Calliditas partner wins China nod for kidney disease therapy